Science 37

Company profile

About Science 37

Science 37 is a modern clinical research site that delivers clinical trials directly to patients' homes, operating as the first and only FDA-inspected direct-to-patient site in the industry. Founded more than a decade ago by investigators with the vision to make clinical research accessible to anyone, anywhere, anytime, the company has supported over 200 clinical trials across Phases I–IV and observational studies. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. With medical licensure across all 50 states, the company's Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to traditional site-based approaches. The company has successfully completed multiple FDA inspections across five Phase 3 studies, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. Science 37's model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20–30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). The company serves pharmaceutical and biotechnology sponsors, helping them accelerate clinical development by connecting patients with research opportunities earlier and making participation more accessible through traditional, hybrid, and decentralized trial models.

Company description · Science 37 official website

Mission. Science 37 was founded more than a decade ago by investigators with the vision to make clinical research accessible to anyone, anywhere, anytime, regardless of their proximity to research sites.